A variation of the short protocol for using GnRH-agonists with injections of follicle stimulating hormone (FSH) for controlled induction of superovulation in assisted conception programs. The GnRH-agonist is started with menstruation, a day or two before the injections of FSH start, and is discontinued after about 5 days from starting it (i.e. often a week or more before ovulation). There are no special advantages, whereas there's a potential disadvantage: a much more thorough suppression of the woman's own luteinising hormone (and maybe FSH) than if the GnRH-agonist is continued -- potentially causing stimulated follicles to 'run out of puff' before they are fully mature. The ultrashort protocol should not be used with pure forms of FSH, such as Fertinex, Gonal-F, Metrodin HP or Puregon, or poor egg quality will result if some luteinising hormone is not administered.

A treatment protocol for controlled stimulation of the ovaries using GnRH-agonists with injections of follicle stimulating hormone (FSH) for induction of superovulation in assisted conception programs involves starting the GnRH-agonist a day or two before the injections of FSH start. The advantage is one of cost: less FSH (and less GnRH-agonist) are used compared with the long protocol. The disadvantage is that luteinising hormone levels and progesterone levels can rise, possibly (in some cycles of treatment) spoiling optimal development of ovarian follicles. The GnRH-agonist is continued (in contrast to the ultrashort protocol) until follicles are mature and human chorionic gonadotropin is given to start the process of ovulation.